Search Results for: "janssen v celltrion"

CELLTRION FILES RESPONSE BRIEF IN INFLIXIMAB APPEAL

As we previously reported, in Janssen v. Celltrion, Janssen appealed the district court’s partial final judgment that Janssen’s ‘471 patent, relating to monoclonal antibodies including infliximab, is invalid. As we also previously reported, Janssen filed its opening appeal brief on January 26, 2017.  On March 7, 2017, Celltrion filed its response brief.  Celltrion argues that…

Read More

JANSSEN FILES OPENING BRIEF IN INFLIXIMAB APPEAL

As we previously reported, in Janssen v. Celltrion, Janssen appealed the district court’s partial final judgment that Janssen’s ‘471 patent, directed to monoclonal antibodies including infliximab or cA2 antibody, is invalid. On January 26, 2017, pursuant to a 30-day extension, Janssen filed its opening appeal brief, in which Janssen challenged the two district…

Read More

Janssen v. Celltrion: Motions to Exclude or Limit Evidence and Testimony from the Upcoming Trial

With the pre-trial conference set to begin on February 6, 2017, the parties in Janssen v. Celltrion have filed several motions seeking to exclude or limit certain evidence and testimony that may be offered at trial. Expert Testimony Celltrion has filed a motion to exclude the opinions of Janssen’s proffered expert…

Read More

JANSSEN FILES SUPPLEMENTAL BRIEF IN INFLIXIMAB LITIGATION

Yesterday, in the Janssen v. Celltrion action, Janssen filed a supplemental brief on the issue of whether Hospira may be liable for infringement on the theories of joint enterprise, agency, or contract.  As we previously reported, the Court ordered the parties to brief this issue after it arose during oral arguments on the motions for…

Read More